Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.27
ILMN's Cash to Debt is ranked lower than
56% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. ILMN: 1.27 )
Ranked among companies with meaningful Cash to Debt only.
ILMN' s Cash to Debt Range Over the Past 10 Years
Min: 0.97  Med: 2.31 Max: 16544
Current: 1.27
0.97
16544
Equity to Asset 0.50
ILMN's Equity to Asset is ranked lower than
68% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. ILMN: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
ILMN' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.60 Max: 0.95
Current: 0.5
0.42
0.95
Interest Coverage 14.55
ILMN's Interest Coverage is ranked lower than
53% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.00 vs. ILMN: 14.55 )
Ranked among companies with meaningful Interest Coverage only.
ILMN' s Interest Coverage Range Over the Past 10 Years
Min: 3.38  Med: 5.73 Max: 67.52
Current: 14.55
3.38
67.52
F-Score: 8
Z-Score: 8.51
M-Score: -2.41
WACC vs ROIC
6.63%
31.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 27.61
ILMN's Operating margin (%) is ranked higher than
95% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. ILMN: 27.61 )
Ranked among companies with meaningful Operating margin (%) only.
ILMN' s Operating margin (%) Range Over the Past 10 Years
Min: -82.12  Med: 18.88 Max: 27.65
Current: 27.61
-82.12
27.65
Net-margin (%) 20.79
ILMN's Net-margin (%) is ranked higher than
94% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. ILMN: 20.79 )
Ranked among companies with meaningful Net-margin (%) only.
ILMN' s Net-margin (%) Range Over the Past 10 Years
Min: -75.89  Med: 12.01 Max: 21.65
Current: 20.79
-75.89
21.65
ROE (%) 26.63
ILMN's ROE (%) is ranked higher than
95% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. ILMN: 26.63 )
Ranked among companies with meaningful ROE (%) only.
ILMN' s ROE (%) Range Over the Past 10 Years
Min: -84.48  Med: 10.45 Max: 27.88
Current: 26.63
-84.48
27.88
ROA (%) 12.85
ILMN's ROA (%) is ranked higher than
89% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. ILMN: 12.85 )
Ranked among companies with meaningful ROA (%) only.
ILMN' s ROA (%) Range Over the Past 10 Years
Min: -43.21  Med: 5.80 Max: 19.92
Current: 12.85
-43.21
19.92
ROC (Joel Greenblatt) (%) 116.07
ILMN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. ILMN: 116.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ILMN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -508.83  Med: 75.57 Max: 136.47
Current: 116.07
-508.83
136.47
Revenue Growth (3Y)(%) 20.10
ILMN's Revenue Growth (3Y)(%) is ranked higher than
90% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ILMN: 20.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ILMN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1  Med: 29.90 Max: 156.2
Current: 20.1
-1
156.2
EBITDA Growth (3Y)(%) 27.40
ILMN's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. ILMN: 27.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ILMN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.6  Med: 22.80 Max: 608.3
Current: 27.4
-73.6
608.3
EPS Growth (3Y)(%) 39.90
ILMN's EPS Growth (3Y)(%) is ranked higher than
87% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ILMN: 39.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ILMN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.7  Med: 8.70 Max: 209.1
Current: 39.9
-40.7
209.1
» ILMN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-21)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

ILMN Guru Trades in Q2 2015

Frank Sands 2,652,228 sh (New)
Steve Mandel 5,678,537 sh (+96.48%)
John Burbank 21,873 sh (+29.89%)
Vanguard Health Care Fund 2,400,500 sh (+24.20%)
Ron Baron 1,509,065 sh (+23.70%)
Julian Robertson 119,900 sh (+16.41%)
First Eagle Investment 400 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 2,239,397 sh (-0.12%)
RS Investment Management 58,580 sh (-3.06%)
Paul Tudor Jones 1,300 sh (-13.33%)
Jim Simons 95,118 sh (-19.61%)
Andreas Halvorsen 4,968,956 sh (-41.59%)
Stanley Druckenmiller 206,500 sh (-49.65%)
» More
Q3 2015

ILMN Guru Trades in Q3 2015

John Griffin 1,015,000 sh (New)
Frank Sands 4,334,855 sh (+63.44%)
RS Investment Management 81,270 sh (+38.73%)
Julian Robertson 158,500 sh (+32.19%)
Jim Simons 123,218 sh (+29.54%)
Vanguard Health Care Fund 3,025,105 sh (+26.02%)
Paul Tudor Jones 1,300 sh (unchged)
First Eagle Investment 400 sh (unchged)
PRIMECAP Management 2,178,040 sh (-2.74%)
Ron Baron 1,458,569 sh (-3.35%)
Stanley Druckenmiller 155,800 sh (-24.55%)
John Burbank 15,838 sh (-27.59%)
Steve Mandel 3,609,735 sh (-36.43%)
Andreas Halvorsen 1,789,486 sh (-63.99%)
» More
Q4 2015

ILMN Guru Trades in Q4 2015

George Soros 2,100 sh (New)
Frank Sands 6,091,448 sh (+40.52%)
Steve Mandel 3,609,835 sh (unchged)
First Eagle Investment 400 sh (unchged)
Samuel Isaly 180,000 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
John Griffin Sold Out
Stanley Druckenmiller Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 2,174,180 sh (-0.18%)
Ron Baron 1,404,071 sh (-3.74%)
Vanguard Health Care Fund 2,787,466 sh (-7.86%)
Julian Robertson 103,200 sh (-34.89%)
RS Investment Management 14,300 sh (-82.40%)
» More
Q1 2016

ILMN Guru Trades in Q1 2016

Vanguard Health Care Fund 2,787,466 sh (unchged)
Samuel Isaly 180,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ILMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Illumina Inc

Baron Funds Comments on Illumina Inc. - Apr 26, 2016

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell during the quarter. Although Illumina reported solid fourth quarter financial results, management tempered the market’s expectations for sales of its HiSeq X and benchtop instruments during early-2016, and shares reacted negatively. We continue to believe that Illumina has a long runway for growth, driven by the increased adoption of DNA sequencing in large clinical markets, such as those for cancer screening, diagnosis, and treatment.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Nov 02, 2015

Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. The company reported disappointing financial results, but we do not believe they reflect a change in the company’s market opportunity. We continue to believe the addressable market for the company’s products and services is large (over $20 billion) and growing as new applications for DNA sequencing emerge. Competitively, we believe Illumina remains the dominant provider of sequencing instruments and consumables. Illumina continues to invest substantially in research and development, and we are optimistic that the company will retain its large technological lead over its potential competitors.



From the Baron Asset Fund shareholder letter Q3 2015 by Andrew Peck.



Check out Ron Baron latest stock trades

Meridian Funds Comments on Illumina - Aug 31, 2015

Illumina (NASDAQ:ILMN) is the leading manufacturer of high-speed machines used to sequence, analyze and "unlock the power of the human genome". The latest flagship product, HiSeq X Ten can sequence DNA at a cost of $1,000 per genome, a five order of magnitude reduction from $100 million cost when this industry was born 15 years ago.



However, at a cost of $1,000 per gene sequence, it would cost $100 million to build a gene library from 100,000 volunteers, thereby pushing researchers to focus on only the most prevalent diseases. Looking ahead, as Illumina continues to drive down gene sequencing cost at a pace faster than Moore's Law, drug companies will continue to assemble larger and larger genomic data sets and invest in increasingly powerful computing clusters to decipher the slightest genetic variations and systematically unlock new knowledge about the human genome.





Note that the cost curve improvement accelerated dramatically in 2007 which coincided with massive value creation in the biotechnology industry. Illumina is also positively impacted the broad move to digitization. Illumina acquired NextBio and is positioning to offer cloud-based delivery of DNA sequencing as a service.





Here is a link to a Reuters story discussing the expansion of DNA sequencing and the gathering of DNA data, called “precision medicine.” http://bit.ly/Precision-Medicine.



From Meridian Growth Fund’s annual letter.



Check out latest stock trades

Baron Funds Comments on Illumina Inc. - Aug 24, 2015

Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. Shares rose on reports of better-than-expected revenue and earnings driven by strong sales of sequencing instruments. We maintain conviction because we believe Illumina holds a monopoly on DNA sequencing at a time when DNA sequencing is increasingly being used in cancer research and diagnosis and reproductive health. (Neal Kaufman)



From Baron Funds' second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Aug 18, 2015

Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. During the past quarter, the company reported revenues and earnings that exceeded most estimates, as a result of strong sales of its core sequencing instruments. We believe that Illumina will maintain its dominant position in the DNA sequencing market and that the demand for sequencing will continue to accelerate. We believe that Illumina’s products will play important roles in several rapidly-growing clinical areas, including the markets for cancer research and diagnosis and reproductive health.





From Baron Funds' second quarter commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 29, 2014

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose 34% in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating.





From Baron Funds' first quarter 2014 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 21, 2014

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman)





From Baron Funds' first quarter 2014 letter to shareholders.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 12, 2014

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman)



From Baron Funds' first quarter 2014 letter to shareholders.



Check out Ron Baron latest stock trades

Top Ranked Articles about Illumina Inc

Baron Funds Comments on Illumina Inc. Guru stock highlight
Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell during the quarter. Although Illumina reported solid fourth quarter financial results, management tempered the market’s expectations for sales of its HiSeq X and benchtop instruments during early-2016, and shares reacted negatively. We continue to believe that Illumina has a long runway for growth, driven by the increased adoption of DNA sequencing in large clinical markets, such as those for cancer screening, diagnosis, and treatment. Read more...
Baron Funds Comments on Illumina Inc. Guru stock higlight
Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. The company reported disappointing financial results, but we do not believe they reflect a change in the company’s market opportunity. We continue to believe the addressable market for the company’s products and services is large (over $20 billion) and growing as new applications for DNA sequencing emerge. Competitively, we believe Illumina remains the dominant provider of sequencing instruments and consumables. Illumina continues to invest substantially in research and development, and we are optimistic that the company will retain its large technological lead over its potential competitors. Read more...
Ron Baron's Largest Purchases During Second Quarter Baron nearly doubles stake in IDEXX Laboratories
Ron Baron (Trades, Portfolio) is the founder of Baron Capital Management, which offers separately managed accounts, sub-advisory services and mutual funds for domestic and international investors. Read more...
Frank Sands Shows Bold Side in Second-Quarter Trades Guru buys and sells several stocks priced at more than $100 per share
Frank Sands (Trades, Portfolio) is CIO/CEO for Sands Capital Management, the firm his father founded more than 20 years ago and has grown from $900 million in assets under management to more than $15 billion. The portfolio of its Select Growth strategy, which emphasizes quick growth and bold vision, produced double-digit returns in 2012 (24.1%) and 2013 (42.2%). Read more...
Meridian Funds Comments on Illumina Guru stock highlight
Illumina (NASDAQ:ILMN) is the leading manufacturer of high-speed machines used to sequence, analyze and "unlock the power of the human genome". The latest flagship product, HiSeq X Ten can sequence DNA at a cost of $1,000 per genome, a five order of magnitude reduction from $100 million cost when this industry was born 15 years ago. Read more...
Baron Funds Comments on Illumina Inc.
Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. Shares rose on reports of better-than-expected revenue and earnings driven by strong sales of sequencing instruments. We maintain conviction because we believe Illumina holds a monopoly on DNA sequencing at a time when DNA sequencing is increasingly being used in cancer research and diagnosis and reproductive health. (Neal Kaufman) Read more...
Baron Funds Comments on Illumina Inc.
Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. During the past quarter, the company reported revenues and earnings that exceeded most estimates, as a result of strong sales of its core sequencing instruments. We believe that Illumina will maintain its dominant position in the DNA sequencing market and that the demand for sequencing will continue to accelerate. We believe that Illumina’s products will play important roles in several rapidly-growing clinical areas, including the markets for cancer research and diagnosis and reproductive health. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 43.86
ILMN's P/E(ttm) is ranked lower than
73% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.55 vs. ILMN: 43.86 )
Ranked among companies with meaningful P/E(ttm) only.
ILMN' s P/E(ttm) Range Over the Past 10 Years
Min: 34.32  Med: 77.73 Max: 344.72
Current: 43.86
34.32
344.72
Forward P/E 32.79
ILMN's Forward P/E is ranked lower than
95% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.16 vs. ILMN: 32.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 43.86
ILMN's PE(NRI) is ranked lower than
72% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.55 vs. ILMN: 43.86 )
Ranked among companies with meaningful PE(NRI) only.
ILMN' s PE(NRI) Range Over the Past 10 Years
Min: 34.5  Med: 77.57 Max: 370.19
Current: 43.86
34.5
370.19
Price/Owner Earnings (ttm) 30.42
ILMN's Price/Owner Earnings (ttm) is ranked lower than
58% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.94 vs. ILMN: 30.42 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ILMN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.68  Med: 39.12 Max: 6540
Current: 30.42
13.68
6540
P/B 10.76
ILMN's P/B is ranked lower than
94% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. ILMN: 10.76 )
Ranked among companies with meaningful P/B only.
ILMN' s P/B Range Over the Past 10 Years
Min: 2.88  Med: 7.45 Max: 23.59
Current: 10.76
2.88
23.59
P/S 9.13
ILMN's P/S is ranked lower than
86% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. ILMN: 9.13 )
Ranked among companies with meaningful P/S only.
ILMN' s P/S Range Over the Past 10 Years
Min: 3.62  Med: 9.15 Max: 17.2
Current: 9.13
3.62
17.2
PFCF 39.28
ILMN's PFCF is ranked lower than
69% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.31 vs. ILMN: 39.28 )
Ranked among companies with meaningful PFCF only.
ILMN' s PFCF Range Over the Past 10 Years
Min: 13.75  Med: 45.56 Max: 136.79
Current: 39.28
13.75
136.79
POCF 30.75
ILMN's POCF is ranked lower than
85% of the 100 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.04 vs. ILMN: 30.75 )
Ranked among companies with meaningful POCF only.
ILMN' s POCF Range Over the Past 10 Years
Min: 10.67  Med: 34.58 Max: 341.94
Current: 30.75
10.67
341.94
EV-to-EBIT 31.48
ILMN's EV-to-EBIT is ranked lower than
69% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.75 vs. ILMN: 31.48 )
Ranked among companies with meaningful EV-to-EBIT only.
ILMN' s EV-to-EBIT Range Over the Past 10 Years
Min: -61.3  Med: 38.00 Max: 381.3
Current: 31.48
-61.3
381.3
EV-to-EBITDA 26.18
ILMN's EV-to-EBITDA is ranked lower than
76% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.31 vs. ILMN: 26.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
ILMN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -77.2  Med: 30.65 Max: 181.7
Current: 26.18
-77.2
181.7
PEG 1.76
ILMN's PEG is ranked higher than
72% of the 60 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.76 vs. ILMN: 1.76 )
Ranked among companies with meaningful PEG only.
ILMN' s PEG Range Over the Past 10 Years
Min: 1.21  Med: 3.21 Max: 13.65
Current: 1.76
1.21
13.65
Shiller P/E 182.70
ILMN's Shiller P/E is ranked lower than
98% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 37.71 vs. ILMN: 182.70 )
Ranked among companies with meaningful Shiller P/E only.
ILMN' s Shiller P/E Range Over the Past 10 Years
Min: 182.42  Med: 673.25 Max: 7200
Current: 182.7
182.42
7200
Current Ratio 3.43
ILMN's Current Ratio is ranked higher than
64% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.64 vs. ILMN: 3.43 )
Ranked among companies with meaningful Current Ratio only.
ILMN' s Current Ratio Range Over the Past 10 Years
Min: 2.22  Med: 4.94 Max: 54.73
Current: 3.43
2.22
54.73
Quick Ratio 2.99
ILMN's Quick Ratio is ranked higher than
71% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. ILMN: 2.99 )
Ranked among companies with meaningful Quick Ratio only.
ILMN' s Quick Ratio Range Over the Past 10 Years
Min: 2.01  Med: 4.54 Max: 54.73
Current: 2.99
2.01
54.73
Days Inventory 122.43
ILMN's Days Inventory is ranked higher than
54% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.92 vs. ILMN: 122.43 )
Ranked among companies with meaningful Days Inventory only.
ILMN' s Days Inventory Range Over the Past 10 Years
Min: 93.73  Med: 119.41 Max: 147.41
Current: 122.43
93.73
147.41
Days Sales Outstanding 63.39
ILMN's Days Sales Outstanding is ranked higher than
51% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.57 vs. ILMN: 63.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
ILMN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.76  Med: 67.64 Max: 86.41
Current: 63.39
56.76
86.41
Days Payable 75.79
ILMN's Days Payable is ranked higher than
63% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.85 vs. ILMN: 75.79 )
Ranked among companies with meaningful Days Payable only.
ILMN' s Days Payable Range Over the Past 10 Years
Min: 51.84  Med: 62.29 Max: 93.62
Current: 75.79
51.84
93.62

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 77.23
ILMN's Price/Net Current Asset Value is ranked lower than
94% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. ILMN: 77.23 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ILMN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.27  Med: 10.41 Max: 2050.89
Current: 77.23
4.27
2050.89
Price/Tangible Book 24.19
ILMN's Price/Tangible Book is ranked lower than
95% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.11 vs. ILMN: 24.19 )
Ranked among companies with meaningful Price/Tangible Book only.
ILMN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.55  Med: 7.10 Max: 62.61
Current: 24.19
1.55
62.61
Price/Projected FCF 3.31
ILMN's Price/Projected FCF is ranked lower than
75% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. ILMN: 3.31 )
Ranked among companies with meaningful Price/Projected FCF only.
ILMN' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.7  Med: 4.67 Max: 17.85
Current: 3.31
1.7
17.85
Price/Median PS Value 1.00
ILMN's Price/Median PS Value is ranked higher than
58% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. ILMN: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
ILMN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.45  Med: 1.04 Max: 16.73
Current: 1
0.45
16.73
Price/Peter Lynch Fair Value 1.75
ILMN's Price/Peter Lynch Fair Value is ranked higher than
68% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.47 vs. ILMN: 1.75 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ILMN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.73  Med: 2.39 Max: 8.67
Current: 1.75
1.73
8.67
Price/Graham Number 6.87
ILMN's Price/Graham Number is ranked lower than
86% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. ILMN: 6.87 )
Ranked among companies with meaningful Price/Graham Number only.
ILMN' s Price/Graham Number Range Over the Past 10 Years
Min: 3.52  Med: 4.85 Max: 14.72
Current: 6.87
3.52
14.72
Earnings Yield (Greenblatt) (%) 3.17
ILMN's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. ILMN: 3.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ILMN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 2.40 Max: 5.9
Current: 3.17
0.3
5.9
Forward Rate of Return (Yacktman) (%) 30.10
ILMN's Forward Rate of Return (Yacktman) (%) is ranked higher than
91% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.62 vs. ILMN: 30.10 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ILMN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -9.3  Med: 0.90 Max: 38.1
Current: 30.1
-9.3
38.1

More Statistics

Revenue(Mil) $2220
EPS $ 3.10
Beta0.67
Short Percentage of Float4.66%
52-Week Range $130.00 - 242.37
Shares Outstanding(Mil)147.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 2,530 2,875 3,375
EPS($) 3.51 4.11 4.98
EPS without NRI($) 3.51 4.11 4.98

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:BDX, XPAR:EI, NYSE:BAX, NYSE:BCR, OCSE:COLO B » details
Traded in other countries:ILU.Germany, ILMN.Mexico,
Illumina Inc was incorporated in California in April 1998 and reincorporated in Delaware in July 2000. The Company provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response. The Company's customers includegenomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The Company's portfolio of integrated systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. This portfolio addresses a range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. It also provides products and services for other life sciences applied markets such as agrigenomics. Government and corporate researchers use its sequencing and array-based tools to accelerate and enhance agricultural research. In addition to selling products, the company provides genotyping, NIPT, and whole-genome sequencing services. The Company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region. In each of these areas, dedicated sales, service, and application-support personnel are expanding and supporting their respective customer bases. In addition, it sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and South Africa. The manufacturing operations require a wide variety of raw materials, electronic and mechanical components, chemical and biochemical materials, and other supplies. Multiple commercial sources provide many of its components and supplies, but there are some raw materials and components that the company obtains from single-source suppliers. The Company's competitors include Affymetrix, Inc., Agilent Technologies, Inc., BGI, Pacific Biosciences of California, Inc., QIAGEN N.V., Roche Holding AG., and Thermo Fisher Scientific, Inc., among others. The Company's operations are regulated by governmental authorities and FDA in the United State.
» More Articles for ILMN

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Illumina Inc. Apr 26 2016 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
Julian Robertson Keeps Buying Citigroup, Netflix, Facebook Dec 07 2015 
Halvorsen's Investment Makes Broadcom His Fifth-Most Valuable Stake Dec 05 2015 
Barron Asset Fund Third Quarter Letter - Part One Nov 02 2015 
Baron Funds Comments on Illumina Inc. Nov 02 2015 
Halvorsen Buys Amazon, Sells Out Micron Technology During Q2 Oct 05 2015 
Ron Baron's Largest Purchases During Second Quarter Sep 28 2015 
Frank Sands Shows Bold Side in Second-Quarter Trades Sep 13 2015 
Perigon Wealth Management's Largest Buys in Second Quarter Sep 08 2015 

More From Other Websites
[$$] A Healthy Prognosis for Drugs and Robots Apr 29 2016
Illumina to Webcast Live Presentation at the Bank of America Merrill Lynch Health Care Conference Apr 27 2016
Large-Cap Update: Illumina’s Stock Tanks on New Earnings Estimate Apr 26 2016
One Year Later: Whatever Happened To Those Biotech Companies? Apr 26 2016
[$$] Charting the Market Apr 22 2016
Premaitha Health patent dispute reaches new level Apr 21 2016
ETF’s with exposure to Illumina, Inc. : April 21, 2016 Apr 21 2016
Illumina Files Patent Infringement Suit in Switzerland against Genoma SA for Infringement of NIPT... Apr 21 2016
Cramer: Looking for a dividend? This is the one to own Apr 20 2016
Facebook Passed 50-Day Test; Netflix, Illumina Broke 2 Support Areas Apr 20 2016
Illumina (ILMN) Shareholder Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces... Apr 20 2016
Illumina, Inc. breached its 50 day moving average in a Bearish Manner : ILMN-US : April 20, 2016 Apr 20 2016
[$$] Illumina Shares Take Hit on Weakness in Europe Apr 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK